<< Back To Search

A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

Notify the Multiple Myeloma Research Foundation you are interested in this trial
NCT06153251
Age 18 +
Sex Both
Phase Phase 1
Third Opinion Trial Synopsis
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. The study focuses on how this treatment can help manage the disease and improve patient outcomes. Here are some key details about the study:
  • The treatment involves a combination of therapies that have shown promise in previous research.
  • Patients will receive personalized care based on their individual health needs and responses to the treatment.
  • This study is unique because it aims to understand how different factors, such as genetics and previous treatments, can influence the effectiveness of the new therapy.
  • Participants will be closely monitored throughout the study to track their progress and any side effects.
  • The goal is to find a more effective way to control the disease and enhance the quality of life for patients.
Overall, this study represents an important step in developing new treatment options that could lead to better management of the disease and improved outcomes for patients.
Third Opinion AI Generated Synopsis

Trial Summary
The purpose of this study is to assess BMS-986453 in participants with relapsed and/or refractory multiple myeloma (RRMM).
from ClinicalTrials.gov

Locations & Contact

Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.

Please share any additional considerations or concerns:
Example: Are you newly diagnosed? What treatments have you already been on?

Contacts: